The following is a summary of “Machine learning for the prediction of mortality in patients with sepsis-associated acute ...

DENVER, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, ...

Chemotherapy regimen shows potential to improve survival and reduce need for surgery in patients with muscle-invasive bladder ...

SeaStar Medical (ICU) announces the shipment of its QUELIMMUNE device to a prominent academic medical center, representing SeaStar Medical’s ...

Metablok is under clinical development by Arch Biopartners and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

TIN-816 is under development for the treatment of sepsis-associated acute kidney injury (SA-AKI) and acute kidney injury ...

EA-230 is under clinical development by Exponential Biotherapies and currently in Phase II for Acute Inflammation.

QUELIMMUNE is the Company’s Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute kidney injury (AKI) and sepsis. “Within weeks ...

Main causes of AKI include sepsis, ischaemia-reperfusion injury and nephrotoxins. Symptoms include fatigue, loss of appetite, headache, nausea and vomiting. Early prediction of Acute kidney injury ...

Nat Rev Nephrol 13: 143-151. 4. Poston JT, Koyner JL (2019): Sepsis associated acute kidney injury. BMJ 364: k4891. 5. Uchino S, Kellum JA, Bellomo R, et al. (2005): Acute renal failure in critically ...

Department of Nephrology, Central Hospital Affiliated to Shenyang Medical College, Shenyang, China Department of Urology, The Third People’s Hospital of Yibin, Yibin, China Outpatient Department, The ...

A new mutation and the first severe case of H5N1 bird flu discovered in a human in Louisiana has raised concern among some ...